Ascletis Pharma, Inc.HKEX: 1672

Next Day Disclosure Return

Oct 26, 2026 at 6:17 AM EDT · Issued by Ascletis Pharma, Inc. via HKEXnews

Filed with HKEX · Stock code 1672 · Oct 26, 2026 at 6:17 AM EDT

On 6ix: 6ix.com/news/next-day-disclosure-return-1614

View Attachment

6ix is reading this filing.

View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix

Earlier from Ascletis Pharma

Voluntary announcement - ascletis announces FDA ind submission of ASC39, an oral small molecule selective amylin receptor agonist for the treatment of obesityOct 26
Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acneOct 23
Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesityOct 20

Later from Ascletis Pharma

Voluntary announcement - ascletis' oral small molecule glp-1, ASC30, demonstrated placebo-adjusted HBA1C reduction of 1.7% at 12 weeks from its U.S. phase ii study in participants with diabetesOct 28

All Ascletis Pharma news releases

Follow Ascletis Pharma into a list and get an email when it puts out news.

Follow Ascletis Pharma